Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fosamprenavir + abacavir + lamivudine
- Development stage
- Phase 3
- Lead developer
- ViiV Healthcare
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**Fosamprenavir (GW433908)** is a water-soluble, phosphate ester prodrug of the HIV-1 protease inhibitor **amprenavir**. It is formulated to reduce pill burden and enhance adherence. When combined with **abacavir** and **lamivudine**, both nucleoside analogue reverse transcriptase inhibitors (NRTIs), this regimen is used for the treatment of human immunodeficiency virus (HIV) infection. Fosamprenavir acts by inhibiting the HIV-1 protease, thereby preventing the viral maturation process required for infectious virion production. Abacavir and lamivudine block reverse transcriptase, halting viral genome replication. Clinical studies demonstrated this combination is potent and generally well tolerated[1][2][4][5].
- Other names
- fosamprenavirGW433908 + abacavir + lamivudine
02
Targets
PR (Progesterone receptor)Human immunodeficiency virus type 1 reverse transcriptase
Beyond the preview
Go deeper on fosamprenavir + abacavir + lamivudine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fosamprenavir + abacavir + lamivudine.